Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

141results about How to "Low acute toxicity" patented technology

Insecticide microcapsule suspension type liquid medicine fertilizer and preparation method and application thereof

The invention discloses an insecticide microcapsule suspension type liquid medicine fertilizer and a preparation method and application thereof.The insecticide microcapsule suspension type liquid medicine fertilizer is prepared from insecticide, an organic solvent, a cyst wall material, a pH adjusting agent I for preparing microcapsules, a nitrogen fertilizer, a phosphate fertilizer, a potash fertilizer, a micronutrient fertilizer, an emulsifying agent, a filler, a dispersing agent, a defoaming agent, a thickening agent, an antifreezing agent and water, wherein the pH adjusting agent I is acid.The raw materials further include a pH adjusting agent II for adjusting the pH value of the liquid medicine fertilizer, wherein the pH adjusting agent II is alkali.The average control effect of the insecticide microcapsule suspension type liquid medicine fertilizer on wheat aphid is 80.0% or above, meanwhile, the yield of eggplants can be increased, and the N, P and K unit nutrient partial productivity is improved.The insecticide microcapsule suspension type liquid medicine fertilizer is simple and reasonable in technology, reduces the material grinding size as much as possible, is low in energy consumption, suitable for industrial production and suitable for being adopted in a small area, and saves material resources, financial resources and labor force.
Owner:CHINA AGRI UNIV

Preparation of avermectin medicament sustained-release nano microsphere preparations and uses thereof

The invention relates to a process for preparing avermectin and derivant dimethylamino avermectin, ivermectin, and doramectin slow release nanometer micro-balloon preparation. The technical procedures comprise suspending the suspending solution of 1%-40% unequal avermectin-type medicine, 0%-4% divinylbenzene (cross linking agent), (metyl group) methyl acrylate of 1% BPO (initiating agent) or solvent of methacrylic acid glycidyl ester in an aqueous phase of 40 DEG C with 1% sodium dodecyl benzene sulfonate and 0.5% gelatine or 0.5% PVA (the size ratio of an oil phase and the aqueous phase is 1:3) in a three-mouth bottle with an agitator, a reflux condensing tube and a thermometer, adding numerous ml of 0.5% methylene blue, regulating ultrasonic homogenization power, heating-up to 61 DEG C at 5 DEG C/10mins after the grain size is even, aggregating for two hours, heating-up to 85 DEG C with the same speed, aggregating for 8 hours and preparing 50nm-100nm avermectin-type medicinal nanometer micro-balloon preparation with different medicine-loading amount, and the packaging and loading rate reaches more than 91%. The invention solves the problem of long-acting controlled release of biological medicament, reduces the toxic and side effect simultaneously, improves the biological availability, reduces the cost and is friendly to the environment.
Owner:INST OF PLANT PROTECTION CHINESE ACAD OF AGRI SCI

Piperazine (piperidine) cyclohexyl derivative and applications of piperazine (piperidine) cyclohexyl derivative in treatment of neuropsychiatric diseases

ActiveCN105367565AGood receptor selectivityImproving the effect of cognitive impairmentOrganic active ingredientsNervous disorderLow affinityAcute toxicity testing
The present invention discloses a piperazine (piperidine) cyclohexyl derivative and applications of the piperazine (piperidine) cyclohexyl derivative in treatment of neuropsychiatric diseases. According to the present invention, the pharmacological experiment results show that the piperazine (piperidine) cyclohexyl derivative provides high affinity with a dopamine D2 receptor, a dopamine D3 receptor, a serotonin 5-HT1A receptor and a serotonin 5-HT2A receptor, provides good D3/D2 receptor selectivity and good 5-HT1A/5-HT2A receptor selectivity, and provides low affinity with alpha receptor; the in vivo test results show that the preferred compound has characteristics of good anti-schizophrenia effect, good pharmacokinetic property, low side effect, low acute toxicity and high safety, and has the development value of being adopted as the novel efficient and low-toxic anti-neuropsychiatric disease; and the piperazine (piperidine) cyclohexyl derivative is a compound represented by the structural general formula (I), or a geometric isomer, an optical isomer, a salt, a hydrate or a solvate thereof. The formula (I) is defined in the specification.
Owner:SHANGHAI INST OF PHARMA IND +1

Melamino-formaldehyde resin encapsulated acetamiprid microcapsule, and preparation method thereof

The invention relates to a melamino-formaldehyde resin encapsulated acetamiprid microcapsule, and a preparation method thereof. The microcapsule is technically characterized by comprising the following components: melamine, a formaldehyde solution, acetamiprid, chloroform, an emulsifying agent, a dispersing agent, water, an acid catalyst and a base catalyst. The preparation method comprises the following steps of: putting melamine and the formaldehyde solution in a three-neck flask, adding the base catalyst and regulating, and heating to obtain a melamino-formaldehyde prepolymer; putting the acetamiprid, chloroform, the emulsifying agent, and water in a reaction flask, and stirring to obtain a pre-emulsification solution; mixing the pre-emulsification solution and the prepolymer, adding acid and catalyzing, and adding an appropriate amount of dispersing agent, raising temperature to 60 DEG C, reacting for three hours and stopping reaction; and washing a product by using water for multiple times, and suction-filtering and drying to obtain a microcapsule product. The encapsulation rate of the microcapsule is relatively high, sustained release time is long, pollution to environment is reduced, the preparation method is simple, wall materials are low in cost and the microcapsule is suitable for large-scale production and application.
Owner:BEIJING UNIV OF CHEM TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products